Fc Engineering

Engineering the Fc domain to selectively enhance or silence binding to specific Fc-gamma receptors (FcγRI, FcγRIIa, FcγRIIIa) to dial in desired effector functions. Key strategies include:

• S239D/I332E mutations: Increase FcγRIIIa affinity 100-fold to potentiate antibody-dependent cellular cytotoxicity (ADCC)
• L234A/L235A (LALA) mutations: Silence FcγR binding to eliminate ADCC and complement-dependent cytotoxicity (CDC)
• Afucosylation: Removing core fucose from the Fc glycan at N297 enhances FcγRIIIa binding without introducing amino acid mutations
• Computational tools like Rosetta and FoldX predict the ΔΔG of mutations at the Fc-FcγR interface to guide rational design

Engineering the pH-dependent interaction between the Fc domain and the neonatal Fc receptor (FcRn) to extend antibody circulatory half-life. Core approaches:

• YTE (M252Y/S254T/T256E) mutations: Increase FcRn binding at pH 6.0 while maintaining release at pH 7.4, extending half-life up to 4-fold
• LS (M428L/N434S) mutations: Enhance FcRn affinity at acidic pH, clinically validated in antibodies like ravulizumab
• Histidine scanning: Introducing pH-sensing residues to engineer conditional binding
• Machine learning models predict FcRn binding affinity from sequence and structural features, enabling high-throughput in silico screening of half-life extension variants

Engineering the Fc CH3 domain to favor correct heavy-chain heterodimerization over homodimer formation, critical for bispecific antibody assembly. Key technologies:

• Knobs-into-Holes (KiH): T366W 'knob' mutation on one chain pairs with T366S/L368A/Y407V 'hole' mutations on the other, achieving >95% heterodimer purity
• Electrostatic steering: Introducing oppositely charged residues (e.g., K409D/K392D vs. D399K/E356K) to favor heterodimeric pairing
• SEEDbody platform: Alternating IgA and IgG CH3 sequences to create structurally complementary domains
• Computational interface design using Rosetta's protein-protein docking and sequence optimization protocols predicts mutation combinations that maximize heterodimer specificity

Modulating the Fc domain's ability to bind C1q and trigger the classical complement cascade. Engineering strategies:

• K326W/E333S mutations: Enhance C1q binding and CDC activity for applications requiring potent complement-mediated killing
• P329G/P331S mutations: Ablate C1q binding to eliminate CDC while preserving FcRn interaction
• IgG subclass shuffling: IgG1 and IgG3 naturally activate complement strongly; IgG2 and IgG4 do not. Engineering IgG1 CH2 domains with IgG4-like loops reduces CDC
• Hexamerization enhancement: Introducing mutations (e.g., E345R) that promote Fc hexamer formation on the cell surface, dramatically increasing C1q avidity and CDC potency

Manipulating the conserved N-linked glycan at N297 to modulate Fc effector functions without altering the protein sequence. Key approaches:

• Afucosylation: Knocking out the FUT8 gene in production cell lines eliminates core fucose, increasing FcγRIIIa binding and ADCC by up to 100-fold
• Bisected glycans: Overexpressing GnTIII adds bisecting GlcNAc, enhancing ADCC
• Sialylation: Increasing terminal sialic acid content promotes anti-inflammatory activity through DC-SIGN receptor engagement
• Machine learning models trained on glycan array data predict how specific glycoforms alter receptor binding profiles, enabling glycoform optimization as a tunable parameter in Fc engineering

Introducing mutations that completely ablate Fc effector functions while preserving structural integrity and FcRn-mediated recycling. Clinical rationale:

• Pure blocking antibodies: When the therapeutic goal is receptor antagonism without cell depletion (e.g., checkpoint inhibitors where T-cell killing is undesirable)
• LALA-PG (L234A/L235A/P329G) mutations: The gold-standard triple mutant that eliminates both FcγR and C1q binding
• IgG4 backbone with S228P: Naturally low effector function with a stabilizing hinge mutation to prevent Fab-arm exchange
• Computational validation ensures silencing mutations do not introduce T-cell epitopes or destabilize the CH2 domain, maintaining developability

In silico modeling of an antibody's ability to engage Fc-gamma receptors (FcγR) on natural killer cells and macrophages to trigger target cell killing. Key design levers include: